Corebridge Financial Inc. Reduces Stock Holdings in Dynavax Technologies Corporation $DVAX

Corebridge Financial Inc. reduced its stake in shares of Dynavax Technologies Corporation (NASDAQ:DVAX) by 1.9% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 68,486 shares of the biopharmaceutical company’s stock after selling 1,320 shares during the quarter. Corebridge Financial Inc.’s holdings in Dynavax Technologies were worth $888,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Cambridge Investment Research Advisors Inc. acquired a new position in shares of Dynavax Technologies in the 1st quarter valued at approximately $312,000. GAMMA Investing LLC raised its position in shares of Dynavax Technologies by 88.4% in the 1st quarter. GAMMA Investing LLC now owns 7,729 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 3,627 shares in the last quarter. First Trust Advisors LP acquired a new position in shares of Dynavax Technologies in the 4th quarter valued at approximately $847,000. Deutsche Bank AG raised its position in shares of Dynavax Technologies by 49.3% in the 4th quarter. Deutsche Bank AG now owns 126,398 shares of the biopharmaceutical company’s stock valued at $1,614,000 after purchasing an additional 41,720 shares in the last quarter. Finally, Northern Trust Corp raised its position in shares of Dynavax Technologies by 10.3% in the 4th quarter. Northern Trust Corp now owns 1,457,848 shares of the biopharmaceutical company’s stock valued at $18,617,000 after purchasing an additional 135,826 shares in the last quarter. 96.96% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

DVAX has been the topic of a number of recent analyst reports. Wall Street Zen raised Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. JMP Securities restated a “market outperform” rating and set a $32.00 price objective on shares of Dynavax Technologies in a research note on Friday, August 22nd. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $24.33.

Dynavax Technologies Price Performance

Shares of NASDAQ DVAX opened at $10.06 on Friday. Dynavax Technologies Corporation has a twelve month low of $9.22 and a twelve month high of $14.63. The company has a current ratio of 6.65, a quick ratio of 6.01 and a debt-to-equity ratio of 0.45. The company has a market capitalization of $1.18 billion, a price-to-earnings ratio of -21.87 and a beta of 1.24. The business has a 50 day simple moving average of $10.63 and a 200-day simple moving average of $11.22.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.12 by $0.02. Dynavax Technologies had a positive return on equity of 5.10% and a negative net margin of 16.67%.The business had revenue of $95.44 million during the quarter, compared to the consensus estimate of $87.55 million. As a group, equities research analysts expect that Dynavax Technologies Corporation will post 0.32 earnings per share for the current year.

Insider Buying and Selling at Dynavax Technologies

In other news, Director Scott Dunseth Myers purchased 3,800 shares of the stock in a transaction dated Friday, August 22nd. The stock was acquired at an average cost of $10.82 per share, for a total transaction of $41,116.00. Following the acquisition, the director owned 35,004 shares of the company’s stock, valued at $378,743.28. The trade was a 12.18% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 2.98% of the company’s stock.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.